58 results on '"Tanasi, I."'
Search Results
2. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study
3. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
4. The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis
5. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia–like or acute lymphoblastic leukemia–like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study
6. Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project
7. P535: UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD).
8. P357: MULTICENTER RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOME OF ADULT PATIENS WITH MIXED-PHENOTYPE ACUTE LEUKEMIA (MPAL) DIAGNOSED AND TREATED IN THE LAST TEN YEARS. A CAMPUS-ALL STUDY.
9. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
10. Corrigendum: 'Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience' (Leukemia Research (2022) 114, (106803), (S0145212622000297), (10.1016/j.leukres.2022.106803))
11. Corrigendum to 'Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience' [Leukemia Res. 114 (March 2022) 106803](S0145212622000297)(10.1016/j.leukres.2022.106803)
12. The Role of Notch and Wnt Signaling in MSC Communication in Normal and Leukemic Bone Marrow Niche
13. Small Molecule Inhibitors of Microenvironmental Wnt/beta-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia
14. PCN188 Identification of Patients with Chronic Myeloid Leukemia (CML), Multiple Myeloma (MM) and Myelodysplastic Syndromes (MDS) Using Real-World DATA: Findings from the Prihta - Ematologia project
15. PB1930 CORRELATION BETWEEN LEVELS OF EARLY MOLECULAR RESPONSE AND BCR-ABL TRANSCRIPT TYPE IN STABLE DMR ATTAINMENT IN CML PATIENTS TREATED WITH IMATINIB
16. PS1461 FAMILIAL OCCURRENCE OF SYSTEMIC AND CUTANEOUS MASTOCYTOSIS IN AN ADULT MULTICENTER SERIES: A REPORT OF 22 CLUSTERED CASES
17. DARATUMUMAB NELLA LEUCEMIA ACUTA LINFOBLASTICA RECIDIVATA O REFRATTARIA. UNO STUDIO DEL CAMPUS ALL
18. INCIDENCE, TREATMENT AND OUTCOME OF CENTRAL NERVOUS SYSTEM RELAPSE IN ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED FRONT-LINE WITH PEDIATRIC-INSPIRED REGIMENS. A RETROSPECTIVE MULTI-CENTER STUDY OF THE CAMPUS ALL
19. Optical aspect of deformation analysis in the bone-denture complex,Opti?ki Aspekt Analize Deformacija Unutar Ko?tano-Proteznog Kompleksa
20. Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts
21. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study
22. Underlying systemic mastocytosis in patients with unexplained osteoporosis: score proposal.
23. Mast Cell Disorders and Hymenoptera Venom-Triggered Anaphylaxis: Evaluation and Management.
24. Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia.
25. Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: A nationwide multicenter retrospective analysis.
26. BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study.
27. The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis.
28. Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study.
29. Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.
30. Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry.
31. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study.
32. Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project.
33. Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study.
34. Update on the Role and Utility of Extracellular Vesicles in Hematological Malignancies.
35. Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study.
36. Corrigendum to "Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience" [Leukemia Res. 114 (March 2022) 106803].
37. Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience.
38. A Multidisciplinary Diagnostic Approach Reveals a Higher Prevalence of Indolent Systemic Mastocytosis: 15-Years' Experience of the GISM Network.
39. Systemic Mastocytosis: Multidisciplinary Approach.
40. The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population.
41. Safety of local anesthesia and prevalence of hypersensitivity reactions in adult patients with clonal mast cell diseases: A retrospective single-center study.
42. Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis.
43. Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series.
44. Bone Marrow Mastocytosis: A Diagnostic Challenge.
45. Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study.
46. The Role of Notch and Wnt Signaling in MSC Communication in Normal and Leukemic Bone Marrow Niche.
47. Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells.
48. Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.
49. High-throughput analysis and functional interpretation of extracellular vesicle content in hematological malignancies.
50. Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.